【摘要】 目的 :观察急性心肌梗死 (AMI)病人链激酶抗体 (SK AB)变化与重组链激酶 (r SK)溶栓疗效的关系。方法 :AMI病人 13例 ,男性 9例 ,女性 4例 ,年龄 56a±s 13a。予r SK 1.5MU于 5%葡萄糖注射液 10 0mL中于 60min内静脉滴注 1次。溶栓前即刻 ,溶栓后 2 ,6,12 ,2 4h ,3d和 7d测定血清SK AB。结果 :溶栓成功者 11例 ,占 85% ;溶栓前平均SK AB滴度为 1∶160 0 ,溶栓后 2h降至 1∶4 0 0 ,并持续至d 3(P <0 .0 1) ,7d明显升高超过 1∶640 0 ;分析溶栓成功者 ,SK AB变化特点相似 ,未发现过敏反应及显著不良反应。结论 :r SK溶栓治疗成功率较高 ,且较安全。SK AB水平高低似与溶栓效果无关。更多还原

【Abstract】 AIM: To observe the dynamic change of antistreptokinase antibodies (SK-AB) before and aftre treatment with recombinant streptokinase (r-SK) in patients suffering from acute myocardial infarction (AMI), and its correlation with clinical efficacy of r-SK. METHODS: Thirteen patients (M 9, F 4; age 56 a± s 13 a) with AMI were given 1.5 MU of r-SK in 5% glucose 100 mL iv drip (within 60 min) in a single injection. The level of SK-AB before and 2, 6, 12, 24 h, 3 d, and 7 d after thrombolytics were determined. RESULTS: (1) Thrombolytic treatment was successful in 11 patients (85%). There was no typical allergic reactions observed. (2) Before thrombolytics, the mean level of SK-AB was 1∶1600. At 2,6,12,24 h and 3 d after r-SK treatment, the titers were at about 1∶400, lower than that before ( P <0.01). The level of SK-AB at 7 d was >1∶6400, higher than that before r-SK treatment ( P <0.05). In the patients with successful thrombolytic treatment, the characteristics of SK-AB change was the same. CONCLUSION: Recombinant-SK had high successful rate and safe for thrombolytic treatment. In patients with AMI, whether the level is high or low of SK-AB, the efficacy is of no consequence. * postgraduate training doctor (Now in Fuxing Hospital, BEIJING 100038, China)更多还原